A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, event driven study in non-dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa
Protocol No: 200808
Investigator: Kianoosh Kaveh, DO
You have been asked to take part in a clinical trial, a type of research study, which we shall refer to as a “study”. This consent form has been reviewed by Quorum Review, an Independent Review Board (IRB). This board reviews research studies to protect the rights and well-being of the people taking part.
Purpose of this Study
You have been asked to participate in this research study of an investigational drug called daprodustat because your kidney doctor has determined that you have anemia associated with chronic kidney disease.
The purpose of this study is to test how effective daprodustat (an investigational drug which has not been approved in the United States by the U.S. Food and Drug Administration [FDA]) is compared with darbepoetin alfa (a drug which has been approved by the FDA to treat anemia associated with chronic kidney disease) for anemia and to see how safely this dosing can be done over a long period of time. Be aware that this form refers to daprodustat and darbepoetin alfa as “study drug.”
Costs of Participation Procedures, study drug and tests that are done only as part of this research study will be provided to you free of charge.
Compensation You will get paid for your participation in this study according to the schedule in the Informed Consent Form. Download it using the button below. Payment ranges from $50-$150 per visit.